Supervisory Board

Professor Christof Hettich has been a member of the Supervisory Board since 2010, was re-elected on 22 July 2020 and is its current Chairman. Professor Hettich is a lawyer and partner at RITTERSHAUS Rechtsanwälte in Mannheim/Frankfurt/Munich. He studied law and political science at the Universities of Freiburg, Würzburg and Mannheim, obtaining his PhD from the University of Würzburg. Professor Hettich has extensive experience in arranging M&A transactions as well as in the structuring and restructuring of medium-sized and public companies. He manages the procurement of private equity financing including the preparation of share issues in sectors such as biotechnology and medical technology.

Dr Georg F. Baur was re-elected to the Supervisory Board on 22 July 2020 and is its current Deputy Chairman. He had already held this position from 28 August 2003 to 30 July 2015 after serving as the Supervisory Board’s chairman from 14 December 2000 to 28 August 2003. Dr Baur works as an entrepreneur in the areas of private investments and asset management. Between 1990 and 1992, he was Managing Partner of Lehndorff Vermögensverwaltungs GmbH. From 1979 to 1989, Dr Baur held various positions at JP Morgan, ultimately as Managing Director and Treasurer of the bank in London. He holds a PhD from the University of St. Gallen, Switzerland.

Dr Mathias Hothum was elected by the Annual General Meeting on 30 July 2015 and re-elected on 22 July 2020. Dr Hothum serves as Managing Director of dievini Verwaltungs GmbH, which in turn acts as the manager of dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, a company that supports and mentors SAP founder Dietmar Hopp in his investments in life sciences and advises the companies from the industry in which Mr Hopp invests on their corporate and business development. Since 1992, Dr Mathias Hothum is owner and managing director of HMM Consulting in Walldorf. With his expertise and experience of twenty years as a self-employed consultant in the area of health care he advised not only companies. He also shared his expertise with students as a lecture at the SRH Hochschule Heidelberg. Dr Hothum received his diplom degree in Economics from the University of Mannheim. He went on to do his PhD at the University of Magdeburg.

Dr Friedrich von Bohlen und Halbach has been a member of the Supervisory Board since 29 April 2005 and was re-elected on 22 July 2020. Dr. von Bohlen und Halbach is CEO and co-founder of Molecular Health GmbH. He holds a diploma in biochemistry from the University of Zurich and a PhD in neurobiology from the Swiss Federal Institute of Technology (ETH) in Zurich. After positions at Fresenius AG, FAG Kugelfischer KGaA and WASAG Chemie AG he co-founded LION bioscience AG in 1997 which CEO he was until 2003. From 2004 until 2022 he managed the biotech investments of the SAP co-founder Dietmar Hopp and his family as co-founder and managing director. He is chairman of the Board of Apogenix AG as well as Board member of Heidelberg Pharma AG. He is also Chairman of InnoSource Ventures AG, Zurich, Member of the Advisory Board of the Wyss Center for Bio and Neuroengineering, Geneva, and member of the board of trustees of the Max Planck Institute for Medical Research, Heidelberg.

Dr Birgit Kudlek has been a member of the Supervisory Board since 25 May 2012 and was re-elected on 22 July 2020. Dr Kudlek has served as Chief Operating Officer and Chief Development Officer as well as Managing Director of AENOVA Holding GmbH in Starnberg. From 2009 to 2013, she was Head of the Sandoz Development Center Network at Sandoz International in Holzkirchen. From 2007 to 2008, she was an Executive Board Member of LTS Lohmann Therapie-Systeme, Andernach, where she was responsible for Technical Operations and Quality. From 2003 to 2007, Dr Kudlek worked for ratiopharm, Ulm, in various management positions within Technical Operations and Development, before taking over responsibility for global development activities. Prior to that Dr Kudlek was employed for more than four years as a consultant at Accenture, Kronberg. She started her career as Managing Assistant at Hoechst Marion Roussel, today Sanofi Aventis, Frankfurt. Birgit Kudlek studied Pharmaceutical Science as well as Economics and holds a PhD in Pharmaceutical Technology from the Technical University of Braunschweig.

Dr. Xia has been the Director of ADC Research Center at Huadong Medicine in Hangzhou, China since 2022. He leads the early research and development of the ADC pipeline and develops Huadong Medicine's R&D strategy. Previously, he served as a senior researcher. In this position, he led the preclinical biology team and conducted several projects, including a collaborative drug discovery project for innovative cancer therapeutics using AI and a preclinical co-discovery and development project. In addition, Dr. Xia has been responsible for due diligence processes for in-licensing or strategic acquisitions, R&D strategies, and pipeline strategies. Dr. Xia holds a Ph.D. in chemical and physical biology from Vanderbilt University, Nashville, Tennessee, USA, and a B.Sc. in biological sciences from Nanyang Technological University, Singapore.